47+ min ago  (406+ words) Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with "ex vivo" medicines like Novartis" Kymriah. Legend"s shares jumped 30% Tuesday following the news. Multiple Wall Street…...

1+ hour, 29+ min ago  (470+ words) Bio Pharma Dive Don't miss tomorrow's biopharma industry news New Limit's $435 M megaround; Lilly's busy dealmaking week The anti-aging biotech has secured one of the year's biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a…...

1+ hour, 26+ min ago  (585+ words) A proposal to add'biotechnology to the COINS Act follows two big deals involving Pfizer and Bristol Myers, and comes amid U. S. fears that China's drugmaking progress may threaten national security. Lower costs and greater regulatory flexibility have turned China into an…...

5+ hour, 44+ min ago  (283+ words) Worth as much as $1. 9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases. Eli Lilly and Ascidian Therapeutics said Wednesday that they're teaming up in a research collaboration to find new medicines for…...

20+ hour, 52+ min ago  (689+ words) Gedatolisib could "establish a new standard of care" for PIK3 CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors. Two drug regimens involving an experimental medicine from Celcuity halved the risk of death or disease progression…...

1+ day, 36+ min ago  (362+ words) Fulcrum's setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics. Fulcrum Therapeutics has begun a strategic review that may result in it getting sold, a move…...

1+ day, 4+ hour ago  (222+ words) A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as "best-in-disease" and sent shares down more than 30%. Abi Vax has had a meteoric rise over the last year thanks to the progress of obefazimod." The…...

1+ day, 21+ hour ago  (252+ words) It's the second attempt for rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB. At the time, Stephen Uden, the CEO of Rallybio, said in a statement that…...

2+ day, 1+ hour ago  (371+ words) The French drugmaker has agreed to acquire an experimental'tablet from'Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion. Servier has, for the past decade, been in what it describes as a state of "deep…...

3+ day, 4+ hour ago  (612+ words) Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that's seen as an important barometer for a class of drugs known as "PD-1/VEGF inhibitors." A double-barreled cancer immunotherapy extended the lives of people…...